Clinical trials
Glioblastoma trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 5 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 6 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Recruiting | 14 |
| Active, not recruiting | 10 |
| Terminated | 4 |
| Not yet recruiting | 2 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| AbbVie | 4 |
| Eli Lilly and Company | 4 |
| Nationwide Children's Hospital | 3 |
| Olivia Newton-John Cancer Research Institute | 3 |
| Telix Pharmaceuticals (Innovations) Pty Limited | 3 |
| Amgen | 2 |
| Hoffmann-La Roche | 2 |
| Nativis, Inc. | 2 |
| PharmAbcine | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glioblastoma | 64 |
| Glioma | 19 |
| Brain Neoplasms | 16 |
| Astrocytoma | 15 |
| Neoplasms | 8 |
| Diffuse Intrinsic Pontine Glioma | 6 |
| Gliosarcoma | 6 |
| Oligodendroglioma | 6 |
| Central Nervous System Neoplasms | 5 |
| Breast Neoplasms | 4 |
Trials
Showing 1 to 25 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.